Prognosis
Dual Flu-Covid Nasal Spray Vaccine to Start Trial in Hong Kong
- About 100 adults will enter the phase-1 study from November
- Research received funding from CEPI and Hong Kong government
This article is for subscribers only.
An experimental dual vaccine for both influenza and the new coronavirus delivered via a nasal spray will enter human studies in Hong Kong next month, a top infectious diseases doctor said.
The early-stage clinical trial will enroll about 100 adults, said Yuen Kwok-Yung, chair of infectious diseases in the University of Hong Kong’s department of microbiology. The candidate vaccine is similar to a nasal spray flu immunization already on the market that’s designed to start working where respiratory viruses typically enter the body: the nose.